Synergistic integration of regional and systemic therapies in uveal melanoma

A new review published in Nature Reviews Clinical Oncology examines the potential of combining percutaneous hepatic perfusion with immune-checkpoint inhibitors for metastatic uveal melanoma, a rare and aggressive eye cancer that frequently spreads to the liver. The authors synthesize recent evidence suggesting that this combination approach may improve patient outcomes compared to either strategy alone. The article compares these findings with data from other clinical trials and identifies critical unanswered questions regarding patient selection, treatment sequencing, and underlying mechanisms of synergy. While not presenting new trial data, the review provides a timely framework for designing future combination strategies in a disease with historically limited treatment options.